Minimal Vitrectomy Surgery for Epiretinal Membrane
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking Union Medical College Hospital
About this trial
This multicenter randomized controlled trial evaluates Minimal Vitrectomy Surgery (MVS) versus conventional vitrectomy for idiopathic epiretinal membrane (ERM). The primary endpoints include visual acuity improvement and cataract progression after 12 months. MVS aims to minimize vitreous removal while ensuring complete membrane removal through adaptive limited vitrectomy.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging.
Clear ocular media allowing adequate fundus imaging.
Phakic eye.
Disqualifiers
Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion).
Systemic conditions preventing safe surgery or follow-up.
History of prior ocular or periocular corticosteroid use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.
Trial design
Treatments tested in this trial
- Minimal Vitrectomy Surgery
- Conventional Vitrectomy
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Peking Union Medical College Hospital
Lead sponsor
Peking Union Medical College
Collaborator
Source ClinicalTrials.gov